Exicure (XCUR) Net Cash Flow (2016 - 2026)
Exicure's (XCUR) quarterly Net Cash Flow came in at -$1.1 million in Q1 2026, up 45.31% YoY from -$785924.9 in Q1 2025, and down 65.03% on a QoQ basis from -$692000.0 in Q4 2025.
Exicure (XCUR) Net Cash Flow (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Net Cash Flow data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Net Cash Flow rose 45.31% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (down 188.28% YoY) and the FY2025 annual result came in at -$8.8 million, down 183.51% from the prior year.
- Net Cash Flow eased to -$1.1 million in Q1 2026, from -$692000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $11.6 million in Q4 2024 to a low of -$18.8 million in Q1 2022.
- A 5-year average of -$2.4 million and a median of -$1.4 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 1913.73% — and 2024, when it soared 11002.83%.
- Tracing XCUR's Net Cash Flow over 5 years: stood at -$7.1 million in 2022, then soared by 98.5% to -$106000.0 in 2023, then soared by 11002.83% to $11.6 million in 2024, then plunged by 105.99% to -$692000.0 in 2025, then sank by 65.03% to -$1.1 million in 2026.
- The last three Net Cash Flow figures came in at -$1.1 million (Q1 2026), -$692000.0 (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | -887,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -692,000.00 |
| Dec 31, 2025 | -692,000.00 |
| Sep 30, 2025 | -3.42 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | 11.56 Mn |
| Dec 31, 2024 | 11.56 Mn |
| Sep 30, 2024 | -449,000.00 |
| Sep 30, 2024 | -449,000.00 |
| Jun 30, 2024 | -166,000.00 |
| Jun 30, 2024 | -166,000.00 |
| Mar 31, 2024 | -450,000.00 |
| Mar 31, 2024 | -450,000.00 |
| Dec 31, 2023 | -106,000.00 |
| Dec 31, 2023 | -106,000.00 |